Butterfly, Graham, Wise Equity target nutraceuticals; Demand for antimicrobial testing drives Astorg’s $1bn carve-out of Thermo Fishers’ microbiology biz
Friday, August 14, 2026 · first reported by PE Hub
Astorg acquiring Thermo Fisher's microbiology business for ~$1bn; Butterfly Equity, Graham Partners, and Wise Equity also targeting nutraceuticals assets.
- Firm
- Astorg
- Deal value
- $1B
- Asset class
- Private equity
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 source- Antin agrees sale of majority stake in Vicinity Energy to Harrison StreetPrivate Equity Wire +3
- CPP Investments sells A$4.5bn Australian toll road stakes to TransurbanIPE Real Assets
- Sycamore nears $9bn sale of Boots to Weston familyPrivate Equity Wire
- Eagle Point backs $450m US government-leased real estate recapitalisationIPE Real Assets
- CSC acquires 50% Watergardens mall stake from QIC for A$480mIPE Real Assets
- Lone Star buys €216m Dutch residential portfolio from Catella fundIPE Real Assets